Proceeds from the OO mostly unused one year laterThe following table shows the estimated use of proceeds, compared with the actual use of proceeds as at February 28, 2022: In millions Estimated Use of Proceeds Actual Use of Proceeds Variance Nash Phase 3 clinical trial $30.5 $2.7 $(27.8) Oncology R&D 7.0 3.7 (3.3) Commercial and marketing activities 3.5 -- (3.5) Other 1.5 1.8 0.3 Net Proceeds $42.5 $8.2 $(34.3) As at February 28, 2022, approximately $2,727,000 had been used in connection with the NASH Phase 3 clinical trial. As at February 28, 2022, approximately $3,697,000 had been used in connection with oncology research and development activities and the variance between the amount reserved and the amount used as at February 28, 2022 represents funds held in cash pending their planned allocation as costs are incurred. Finally, the Company has not implemented new initiatives in terms of commercial and marketing activities, such that the funds earmarked for such use have been added to the Company’s working capital. First-Quarter Fiscal 2022 Financial Resul